Literature DB >> 7923750

Cyclosporine: mechanisms of action and toxicity.

R M Graham1.   

Abstract

BACKGROUND: Newer immunosuppressive agents are permitting transplantation to be performed more frequently.
OBJECTIVES: To review the mechanisms of action and toxicity of cyclosporine. DISCUSSION: Graft rejection is mainly cell-mediated, although a humoral (antibody) response may also be involved. Cyclosporine and related agents such as FK-506 and rapamycin selectively inhibit adaptive immune responses by blocking T cell-dependent biosynthesis of lymphokines, particularly interleukin 2 at the level of messenger ribonucleic acid (mRNA) transcription. Because cyclosporine is metabolized in the liver by P-450 enzymes, drugs that affect the P-450 system also affect the metabolism of cyclosporine. Hypertension is the most common side effect of cyclosporine. Cyclosporine-induced "nephrotoxicity" may be functional rather than anatomic, caused primarily by preferential constriction of the afferent renal arteriole. Bacterial and fungal infections are less common with regimens of cyclosporine plus prednisone than with azathioprine plus prednisone. Nevertheless, cyclosporine-treated patients are vulnerable to viral infections.
CONCLUSIONS: Although cyclosporine and related compounds represent an improvement over earlier immunosuppressive agents, they produce serious side effects with which the practitioner should be familiar.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923750     DOI: 10.3949/ccjm.61.4.308

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  16 in total

1.  The effect of two different polyethylene glycol (PEG) derivatives on the immunological response of PEG grafted pancreatic islets.

Authors:  Hamideh Aghajani-Lazarjani; Ebrahim Vasheghani-Farahani; Seyed Abbas Shojaosadati; Sameereh Hashemi-Najafabadi; Saleh Zahediasl; Taki Tiraihi; Fatemeh Atyabi
Journal:  J Artif Organs       Date:  2010-12-04       Impact factor: 1.731

2.  Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty.

Authors:  Jong Joo Lee; Mee Kum Kim; Won Ryang Wee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-21       Impact factor: 3.117

Review 3.  Switching between cyclosporin formulations. What are the risks?

Authors:  A J Olyaei; A M deMattos; W M Bennett
Journal:  Drug Saf       Date:  1997-06       Impact factor: 5.606

4.  Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform.

Authors:  Gene L Bidwell
Journal:  Physiology (Bethesda)       Date:  2021-09-06

Review 5.  Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia.

Authors:  HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

Review 6.  Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).

Authors:  S Noble; A Markham
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

7.  Exercise Performance in Pediatric Liver Transplant Recipients and Its Related Cardiac Function.

Authors:  Seyed Mohsen Dehghani; Mitra Moshref; Hamid Amoozgar; Seyed Ali Malek Hoseini; Saman Nikeghbalian
Journal:  Pediatr Cardiol       Date:  2017-12-14       Impact factor: 1.655

8.  Co-administration of the flavanol (-)-epicatechin with doxycycline synergistically reduces infarct size in a model of ischemia reperfusion injury by inhibition of mitochondrial swelling.

Authors:  Pilar Ortiz-Vilchis; Katrina Go Yamazaki; Ivan Rubio-Gayosso; Israel Ramirez-Sanchez; Claudia Calzada; Diego Romero-Perez; Alicia Ortiz; Eduardo Meaney; Pam Taub; Francisco Villarreal; Guillermo Ceballos
Journal:  Eur J Pharmacol       Date:  2014-10-02       Impact factor: 4.432

Review 9.  Annexin-A1: a pivotal regulator of the innate and adaptive immune systems.

Authors:  F D'Acquisto; M Perretti; R J Flower
Journal:  Br J Pharmacol       Date:  2008-07-21       Impact factor: 8.739

10.  Diagnosis and treatment of status epilepticus in a pediatric renal recipient.

Authors:  Gao Hongjun; Luo Xiangdong; Liang Taisheng; Lu Shangguang; Liang Fangfang; Dong Yu; Tan Zhen; Wu Zhen
Journal:  Case Rep Transplant       Date:  2012-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.